Guía de Práctica Clínica sobre Trastorno Bipolar - GuíaSalud

disorder: a post hoc analysis of combined results from 2 double-blind, randomized,
placebo-controlled studies. J Clin Psychiatry, 2008; 69 (5): 769-782.
244. Young AH, McElroy SL, Bauer M, Philips N, Chang W, Olausson B, Paulsson B y
Brecher M. A double-blind, placebo-controlled study of quetiapine and lithium
monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin
Psychiatry, 2010; 71 (2): 150-162.
245. Cruz N, Sanchez-Moreno J, Torres F, Goikolea JM, Valenti M y Vieta E. Efficacy of
modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis.
Int J Neuropsychopharmacol, 2010; 13 (1): 5-14.
246. Deeks ED y Keating GM. Olanzapine/fluoxetine: a review of its use in the treatment of
acute bipolar depression. Drugs, 2008; 68 (8): 1115-1137.
247. Tamayo JM, Zarate CA, Jr., Vieta E, Vazquez G y Tohen M. Level of response and
safety of pharmacological monotherapy in the treatment of acute bipolar I disorder
phases: a systematic review and meta-analysis. Int J Neuropsychopharmacol, 2010; 13
(6): 813-832.
248. Vieta E, Locklear J, Gunther O, Ekman M, Miltenburger C, Chatterton ML, Astrom M y
Paulsson B. Treatment options for bipolar depression: a systematic review of randomized,
controlled trials. J Clin Psychopharmacol, 2010; 30 (5): 579-590.
249. Sachs GS, Ice KS, Chappell PB, Schwartz JH, Gurtovaya O, Vanderburg DG y Kasuba
B. Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in
patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J
Clin Psychiatry, 2011; 72 (10): 1413-1422.
250. Tohen M, Kryzhanovskaya L, Carlson G, Delbello M, Wozniak J, Kowatch R, Wagner
K, Findling R, Lin D, Robertson-Plouch C, Xu W, Dittmann RW y Biederman J.
Olanzapine versus placebo in the treatment of adolescents with bipolar mania. The
American Journal of Psychiatry, 2007; 164 (10): 1547-1556.
251. Tondo L, Baldessarini RJ y Floris G. Long-term clinical effectiveness of lithium
maintenance treatment in types I and II bipolar disorders. British Journal of Psychiatry,
2001; Suppl 41: s184-s190.
252. Cipriani A, Pretty H, Hawton K y Geddes JR. Lithium in the prevention of suicidal
behavior and all-cause mortality in patients with mood disorders: a systematic review of
randomized trials. The American Journal of Psychiatry, 2005; 162 (10): 1805-1819.
253. Ahrens B y Muller-Oerlinghausen B. Does lithium exert an independent antisuicidal
effect? Pharmacopsychiatry, 2001; 34 (132-136).
254. Angst J, Angst F, Gerber-Werder R y Gamma A. Suicide in 406 mood-disorder patients
with and without long-term medication: a 40 to 44 years' follow-up. Arch Suicide Res,
2005; 9 (3): 279-300.
255. Kessing LV y Andersen PK. Predictive effects of previous episodes on the risk of
recurrence in depressive and bipolar disorders. Current psychiatry reports, 2005; 7 (6):
413-420.
256. Baldessarini RJ, Tondo L, Davis P, Pompili M, Goodwin FK y Hennen J. Decreased risk
of suicides and attempts during long-term lithium treatment: a meta-analytic review.
Bipolar disorders, 2006; 8 (5 Pt 2): 625-639.
257. Collins JC y McFarland BH. Divalproex, lithium and suicide among Medicaid patients
with bipolar disorder. J Affect Disord, 2008; 107 (1-3): 23-28.
258. Oquendo M, Galfalvy H, Currier D, Grunebaum M, Sher L, Sullivan G, Burke A,
Harkavy-Friedman J, Sublette M, Parsey R y Mann J. Treatment of suicide attempters
with bipolar disorder: a randomized clinical trial comparing lithium and valproate in the
prevention of suicidal behavior. Am J Psychiatry, 2011; 68 (10): 1050-1056.
259. Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E y Rudd GD. A doubleblind
placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I
depression. Lamictal 602 Study Group. J Clin Psychiatry, 1999; 60 (2): 79-88.
260. Davis LL, Bartolucci A y Petty F. Divalproex in the treatment of bipolar depression: A
placebo controlled trial. Journal of affective disorders, 2005; 85: 259-266.
414 SANIDAD